New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Research Site, Belleville, New Jersey
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
The THOR IDE Study
NCT05916950
Recruiting
The goal of this clinical trial is to test the Thor system in adult (ā‰„ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating these lesions * Does the Thor system work to treat these lesions Participants will: * Receive treatment with the Thor system * Have follow-up visits at Discharge, 30 days, 6 months, and 12 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Heart and Vascular Institute of Central Jersey, New Brunswick, New Jersey
Conditions: Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Register for Updates
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Register for Updates
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843
Recruiting
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to sever... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: Sanmora Bespoke Clinical Research Solutions- Site Number : 8400016, East Orange, New Jersey
Conditions: Colitis Ulcerative
Register for Updates
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Astera Cancer Care, East Brunswick, New Jersey
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329
Recruiting
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MSK Basking Ridge, Basking Ridge, New Jersey
Conditions: Urothelial Carcinoma
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Cardiovascular Associates of the Delaware Valley, Haddon Heights, New Jersey
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
NCT02704858
Recruiting
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Atlantic Health (Overlook Medical Center), Summit, New Jersey
Conditions: Glioblastoma Multiforme
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: Cooper Health Center- Site Number : 840098, Camden, New Jersey
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
LIVERAGEā„¢ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: IMA Clinical Research-Warren-69742, Warren, New Jersey
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Register for Updates
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324
Recruiting
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: AtlantiCare, Egg Harbor Township, New Jersey
Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Register for Updates
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830
Recruiting
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: Bio Behavioral Health, Toms River, New Jersey
Conditions: Treatment Resistant Depression
Register for Updates